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OBJECTIVE—Hepatocyte nuclear factor 1-a (HNF1A)/hepatocyte nuclear factor 4-a
(HNF4A) maturity-onset diabetes of the young (MODY) is frequently misdiagnosed as type 1
diabetes, and patients are inappropriately treated with insulin. Blood C-peptide can aid in the
diagnosis of MODY, but practical reasons limit its widespread use. Urinary C-peptide creatinine
ratio (UCPCR), a stable measure of endogenous insulin secretion, is a noninvasive alternative.
We aimedto compare stimulatedUCPCRinadultswithHNF1A/4AMODY,type 1diabetes,and
type 2 diabetes.
RESEARCH DESIGN AND METHODS—Adults with diabetes for $5years, without
renal impairment, were studied (HNF1A MODY [n = 54], HNF4A MODY [n =2 3 ] ,g l u c o k i n a s e
MODY [n=20],type1diabetes[n=69],andtype2diabetes[n=54]).TheUCPCRwascollected
in boric acid 120 min after the largest meal of the day and mailed for analysis. Receiver operating
characteristic (ROC) curves were used to identify optimal UCPCR cutoffs to differentiate
HNF1A/4A MODY from type 1 and type 2 diabetes.
RESULTS—UCPCR was lower in type 1 diabetes than HNF1A/4A MODY (median [interquar-
tile range]) (,0.02 nmol/mmol [,0.02 to ,0.02] vs. 1.72 nmol/mmol [0.98–2.90]; P ,
0.0001). ROC curves showed excellent discrimination (area under curve [AUC] 0.98) and
identiﬁed a cutoff UCPCR of $0.2 nmol/mmol for differentiating HNF1A/4A MODY from type
1 diabetes (97% sensitivity, 96% speciﬁcity). UCPCR was lower in HNF1A/4A MODY than in
type2diabetes(1.72nmol/mmol[0.98–2.90]vs.2.47nmol/mmol[1.4–4.13]);P=0.007).ROC
curves showed a weak distinction between HNF1A/4A MODY and type 2 diabetes (AUC 0.64).
CONCLUSIONS—UCPCR is a noninvasive outpatient tool that can be used to discriminate
HNF1A and HNF4A MODY from long-duration type 1 diabetes. To differentiate MODY from
type1diabetesof.5years’duration,UCPCRcouldbeusedtodeterminewhethergenetictesting
is indicated.
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M
aturity-onset diabetes of the
young (MODY) describes domi-
nantly inherited young-onset
non–insulin-dependent diabetes (often
,25 years’ duration) with persistent en-
dogenous insulin secretion (1,2). Hetero-
zygous activating mutations in the
transcription factor genes hepatocyte nu-
clear factor 1-a (HNF1A) and hepatocyte
nuclear factor 4-a (HNF4A) are common
causesofmonogenicdiabetes,accounting
for 52 and 10% of MODY cases, respec-
tively (3)
Recognition and genetic diagnosis of
HNF1A/4A MODY is crucial for optimal
management. HNF1A/4A MODY fre-
quently is misdiagnosed as type 1 diabe-
tes because patients are diagnosed young
(mean age of diagnosis: HNF1A age 20
years and HNF4A age 23 years) and are
nonobese (4–6). In our diagnostic genet-
ics service in Exeter, of 405 referrals for
HNF1A MODY, 140 (35.5%) initially
were misdiagnosed with type 1 diabetes
and inappropriately treated with insulin
(R.E.J.B.,S.E.,A.T.H.,unpublisheddata).
Patients are extremely sulfonylurea sensi-
tiveand, oncediagnosed, often are ableto
stop insulin treatment (6–8).
Genetic testing is needed to conﬁrm
HNF1A and HNF4A MODY, but it is too
costly to be used to screen all patients
with diabetes. An alternative cheap and
practical biomarker to identify patients
with a higher probability of HNF1A/4A
MODY for genetic testing would improve
diagnosis.
Various biomarkers have been pro-
posed (apoliprotein M, complement 5
[C5], complement 8 [C8], transthyretin
[TTR],and1,5-anhydroglucitol).Allhave
attempted to discriminate HNF1A or
HNF4A MODY from type 2 diabetes
rather than type 1 diabetes (9–13), but
they were not sufﬁciently accurate for
routine clinical use.
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ORIGINAL ARTICLEC-peptide is a good candidate bio-
marker to differentiate patients with
MODY from type 1 diabetes. C-peptide
is a polypeptide cosecreted in equimolar
amounts with insulin. Measurement of
blood C-peptide is available in hospital
and will identify patients who still are
making their own insulin. In type 1 di-
abetes, autoimmune destruction of
b-cells results in absolute insulin deﬁ-
ciency,usuallywithin5yearsofdiagnosis
(14). In HNF1A and HNF4A MODY,
b-cell function is maintained despite a
reduction in insulin secretion and pro-
gressive hyperglycemia (15,16). Blood
C-peptide outsidethe honeymoon period
should alert the clinician to a diagnosis of
MODY(17).AlthoughbloodC-peptide is
available, it is not routinely measured be-
cause of practical limitations. The rapid
degradationbyproteasesmeansthatsam-
ples need tobeseparatedandfrozen prior
to analysis, restricting testing to the hos-
pital setting (18). C-peptide usually is
measured after stimulation with a mixed
meal or glucagon to detect b-cell reserve
(19), and the need to discontinue short-
acting insulin prior to testing may further
limit its clinical use.
C-peptide is renally metabolized, and
5–10% of C-peptide is excreted un-
changedinurine(20).UrinaryC-peptide,
creatinine ratio (UCPCR) is a useful alter-
native method to measuring C-peptide,
and the use of a creatinine ratio accounts
for the effects in urine concentration.
UCPCR is stable for 3 days in boric acid
preservative at room temperature, offering
the potential to use postal samples in the
community (21). No studies to date have
used UCPCR to differentiate MODY from
other types of diabetes.
We hypothesize that endogenous in-
sulin secretion persists in HNF1A/4A
MODY, and UCPCR will discriminate
HNF1A/4A MODY from type 1 in long-
standing diabetes. The aim of this study
was to compare stimulated UCPCR in
adults with HNF1A/4A MODY, type 1
diabetes, and type 2 diabetes.
RESEARCH DESIGN AND
METHODS—Adults with diabetes of
$5y e a r s ’ duration were identiﬁed from
existing research databases at the Penin-
sula Medical School, Exeter, U.K., and
from routine diabetes clinics. Because
C-peptide is metabolized largely in the
kidney, patients were excluded from tak-
ing part if they had known renal impair-
ment (estimated glomerular ﬁltration rate
,60 ml/min per 1.73 m
2). A total of 97
patients with a genetic diagnosis of
MODY were recruited (54 patients with
mutations in the HNF1A gene, 23 with
HNF4A mutations, and 20 with glucoki-
nase [GCK] mutations). A total of 69 pa-
tients with type 1 diabetes were studied
(deﬁned as those who had an age of di-
agnosis of ,30 years and on insulin since
diagnosis) as well as 54 patients with type
2diabetes(deﬁned asthosewithan ageof
diagnosisof$35 yearsandnoton insulin
for the ﬁrst year of diagnosis). Patients
were contacted initially either by letter or
bytheirhealthcareprofessional.Follow-up
contact was made by telephone by the re-
search team, and the following informa-
tion was documented: age of diagnosis,
current medication, A1C, creatinine,
weight, and height. Consent was gained
tocontactthepatient’sgeneralpractition-
ers for missing information.
Sample collection
Urine containers with boric acid preser-
vativeweremailedtoparticipants.Aurine
sample was collected 120 min after com-
pleting the largest meal of the day, having
voided prior to eating. Participants took
their normal medication during the test.
The sample was either mailed the same
day or refrigerated overnight and mailed
ﬁrst class to the research laboratory the
following morning. Samples were ana-
lyzed only if they reached the biochemis-
try laboratory within 72 h of the sample
void.
Ethics
The study was approved by the Devon
and Torbay Research and Ethics Commit-
tee. All subjects gave informed consent.
UCPCR analyses
Urinary C-peptide was measured by elec-
trochemiluminescence immunoassay
(intra-assay coefﬁcient of variation ,3.3%;
interassay coefﬁcient of variation ,4.5%)
on a Roche Diagnostics (Mannheim, Ger-
many) E170 analyzer by the biochemistry
department at the Royal Devon and Exeter
National Health Service Foundation Trust,
Exeter, U.K. Urinary creatinine was ana-
lyzed on the Roche P800 platform using
creatinine Jaffé reagent (standardized
against isotope dilution mass spectrome-
try) to UCPCR (nmol/mmol).
Statistical analysis
Results are presented as medians (inter-
quartile range), unless otherwise stated.
Patients with HNF1AandHNF4AMODY
were combined for the purposes of the
analyses because there was no signiﬁcant
difference in UCPCR values (P = 0.87),
clinical characteristics, or treatment be-
tween the two groups (Supplementary
Table 1).
Characteristics of patients in the
HNF1A/4A MODY and type 1 diabetic
(or type 2 diabetic) groups were com-
pared using a x
2 or generalized Fisher ex-
act test for categorical data (sex and
treatment) and Mann-Whitney U test for
continuous variables not normally dis-
tributed (ageof diagnosis, currentage, di-
abetes duration, BMI, and UCPCR).
Receiver operating characteristic (ROC)
curves were used to identify cutoffs of
UCPCR that provided the optimal sensi-
tivity and speciﬁcity for discriminating
HNF1A/4A MODY from type 1 diabetes
(which we deﬁned as absolute insulin de-
ﬁciency) and HNF1A/4A MODY from
type 2 diabetes. Analysis was repeated ex-
aminingonlythosewhoweretreatedwith
insulin. Likelihood ratios were calculated
to estimate the effect of a UCPCR value
abovethecutoffidentiﬁed todiscriminate
between HNF1A/4AMODYand type1 or
type 2 diabetes to calculate a posttest
probability.
Statistical analysis was performed us-
ing SPSS version 15, and P , 0.05 was
assumed to be signiﬁcant.
Assessment of patients with type 1
diabetes with persistent C-peptide
Type 1 diabetic patients who were iden-
tiﬁed as having UCPCR values greater
than the identiﬁed cutoff for insulin de-
ﬁciency (as deﬁned by ROC analysis)
provided a repeat urine sample and were
contacted again for a mixed-meal toler-
ance test. Patients arrived having fasted
and were given an Ensure high-protein
milkshake(6ml/kg,maximum360ml).A
sample was taken at 90 min for measure-
mentofstimulatedserumC-peptide(19),
with a value of 0.2 nmol/L indicating per-
sistent endogenous insulin production
(14,22). These patients also were tested
for GAD and IA2 antibodies, and the
HNF1A and HNF4A genes were se-
quenced. Pancreatic antibodies were con-
sidered positive if .99th percentile of
500 control samples.
RESULTS—Patient characteristics are
presented in Table 1.
HNF1A/4A MODY versus type 1
diabetes
Postprandial UCPCR was markedly lower
intype1diabetesthanHNF1A/4AMODY
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Besser and Associates(median [interquartile range]; ,0.02
nmol/mmol [,0.02 to ,0.02] vs. 1.72
nmol/mmol [0.98–2.90]; P , 0.0001)
(Fig. 1A). ROC curves showed excellent
discrimination (area under curve [AUC]
0.98) and identiﬁed a cutoff UCPCR
$0.2 nmol/mmol for discriminating
HNF1A/4A MODY from type 1 diabetes
with 97% sensitivity and 96% speciﬁcity
(Fig. 1B). This translates to a likelihood
ratio of 24 for identifying HNF1A/4A
MODY using a UCPCR $0.2 nmol/mmol.
This relationship persisted when
assessing the discrimination of insulin-
treated HNF1A/HNF4A from type 1
subjects (AUC 0.96, 94% sensitivity,
and 96% speciﬁcity) (Supplementary
Fig.1).Weshowedthatdiabetesduration
did not interfere with the discriminatory
ability of UCPCR by performing further
analysis on 50 HNF1A/4A MODY and
50 type 1 diabetic patients, matched
within 62 years’ diabetes duration, and
afurthersubanalysisonpatientswith5–25
years’ diabetes duration (Supplementary
results).
UCPCR-positive type 1 diabetes
We went on to study further the 3 of 69
(4%) type 1 diabetic patients with di-
abetes duration of $5 years who had a
UCPCR $0.2 nmol/mmol. All three pa-
tients remained positive on repeat UCPCR
testing. Two of three patients exceeded the
serumC-peptideconcentrationthatisused
to deﬁne signiﬁcant endogenous insulin
Table 1—Patient characteristics
HNF1A/4A MODY Type 1 diabetes
P value (MODY
vs. type 1
diabetes) Type 2 diabetes
P value (MODY
vs. type 2
diabetes)
n (% male) 77 (42.9) 69 (47.8) 0.55 54 (44.4) 0.86
Age of diagnosis (years) 22 (15–30) 13 (8–19) ,0.0001* 60 (50.8–65.3) ,0.0001*
Age (years) 46.6 (38.1–64.3) 45.4 (37–58.4) 0.21 72 (66.3–75.4) ,0.0001
Duration of diabetes (years) 23.1 (14.7–35.4) 33.5 (21.9–42.2) 0.002* 11.4 (8.7–15.3) ,0.0001*
BMI (kg/m
2)2 4 . 3 ( 2 2 . 4 –26.7) 26.3 (24.0–29.0) 0.004* 28.5 (26.1–32.7) ,0.0001*
Treatment (n) ,0.0001* 0.48
Diet alone 4 0 6
OHA alone 42 0 29
Insulin with or without OHA 31 69 19
A1C (%) 7.4 (6.6–8.0)† 7.9 (7.3–8.9) 0.001* 7.6 (7.0–8.2) 0.223
Parent affected (n [%]) 70 (91) 16 (23)
Three or more consecutive
generations affected 64 (83) 6 (9)
UCPCR (nmol/mmol) 1.72 (0.98–2.9) ,0.02 (,0.02 to ,0.02) ,0.0001* 2.47 (1.4–4.13) 0.007*
Data are median (interquartile range), unless otherwise stated. OHA, oral hypoglycemic agent. *Statistical signiﬁcance. †Missing data for A1C; HNF1A/4A MODY
(n = 20).
Figure 1—Box plot and ROC curve to identify HNF1A/4A MODY from type 1 diabetes. A: Box plot to show the UCPCR in HNF1A/4A MODY (n =
77)andtype1diabetes(n=69).DottedlineindicatesaUCPCRcutoffof0.2nmol/mmol.Circles,outliers;stars,extremeoutliers.B:TheROCcurve
identiﬁed a cutoff UCPCR $0.2 nmol/mmol for discriminating HNF1A/4A MODY from type 1 diabetes (AUC 0.98) with 97% sensitivity and 96%
speciﬁcity.
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UCPCR: HNF1A/4A MODY vs. type 1 diabetessecretion(0.2nmol/l)(22),despitediabetes
duration of over 25 years (Supplementary
Table 2). Two of three patients had either
elevated GAD65 or IA2 antibodies (see
supplementary material), and none of
these patients had mutations in HNF1A
and HNF4A genes.
HNF1A/4A MODY versus type 2
diabetes
Although postprandial UCPCR was lower
i nH N F 1 A / 4 AM O D Yt h a ni nt y p e2
diabetes (1.72 nmol/mmol [0.98–2.90]
vs. 2.47 nmol/mmol [1.4–4.13]; P =
0.007), the ROC curve (Fig. 2) showed
weak discrimination between HNF1A/
4A MODY and type 2 diabetes (AUC
0.64). A UCPCR #3.1 nmol/mmol could
discriminate HNF1A/4A MODY from
type 2 diabetes with 81% sensitivity and
44% speciﬁcity. In patients treated with
insulin, UCPCR was better, identifying a
cutoff of 1.27 for discriminating type 2
diabetes (n = 19) from HNF1A/4A
MODY (n = 31), (AUC 0.69, 74% sensitiv-
ity, and 68% speciﬁcity) (Supplementary
Fig.2).UCPCRresultsdidnotdifferentiate
HNF1A/4A MODY from type 2 diabetes in
patients treated with oral agents (AUC
0.54, P = 0.55) (Supplementary Fig. 3).
MODY subtypes (HNF1A, HNF4A,
and GCK MODY)
There was no difference in UCPCR be-
tween HNF1A and HNF4A MODY (1.72
nmol/mmol [0.90–2.90] vs. 1.48 nmol/
mmol [1.01–2.93]; P = 0.87), but com-
bined values were signiﬁcantly lower
than GCK MODY (1.72 nmol/mmol
[0.98–2.90] vs. 3.1 nmol/mmol [2.16–
4.05];P=0.002)(SupplementaryTable1).
CONCLUSIONS—In this study,
UCPCR showed excellent discrimination
between HNF1A/HNF4A MODY and
type 1 diabetes in patients .5 years after
diabetes diagnosis, suggesting that this
isausefultooltodetectpatientswithpos-
sibleHNF1AorHNF4AMODYinclinical
practice.
UCPCR compared with serum
C-peptide
We have shown that a value of $0.2
nmol/mmol is highly speciﬁc (96%)
and sensitive (97%) in discriminating
HNF1A/HNF4A MODY from type 1 dia-
betes when patients are tested .5y e a r s
after diagnosis.Thishighlevel of discrim-
inationremainsevenwhentheMODYpa-
tients are treated with insulin. The ability
to discriminate whether an insulin-
treated patient should be considered for
geneticanalysisisimportantfordiagnosis
and family screening. Finding a UCPCR
.0.2 nmol/mmol would suggest that a
genetic test may be appropriate. If a diag-
n o s i so fH N F 1 A / 4 AM O D Yi sm a d ei n
a patient treated with insulin from diag-
nosis, this may bring about treatment
change (6–8). A diagnosis of monogenic
diabetes also has implications for the ge-
netic testing of other family members.
This test cannot be used close to
diagnosis because persistent C-peptide is
likely to still be present in patients with
type1diabetesintheﬁrstfewmonthsand
occasionally years after diagnosis (14). In
cases where there is an affected parent,
this will usually be of long duration at
the time the child is ﬁrst diagnosed. If
the parents’ durationis.5 years, UCPCR
testing and, if appropriate, subsequent
genetic testing could be performed in
the parent.
This result is not surprising because
persistent endogenous insulin secretion
resulting in patients not being insulin
dependent is a key feature of MODY
(1,2). It already has been established
that serum C-peptide is likely to be per-
sistentinMODY(1,8,15,16),andthiscan
be used to distinguish it from type 1 di-
abetes (23). Our results from patients
who had both a serum C-peptide mea-
sured in a mixed-meal tolerance test and
UCPCR show that the results are similar
andbothcandetectrelativelylowlevelsof
endogenous insulin secretion.
The major advantage of UCPCR over
serum C-peptide is its practical utility.
Serum C-peptide requires separating
the serum by spinning rapidly and sub-
sequent freezing of the sample. This effec-
tively limits its use to hospital settings
Figure 2—Box plot and ROC curve to identify HNF1A/4A MODY from type 2 diabetes. A: Box plot to show the UCPCR in HNF1A/4A MODY (n =
77)andtype2diabetes(n=54).Circles,outliers;stars,extremeoutliers.B:TheROCcurveindicatesthatUCPCRwasnotabletoeasilydiscriminate
HNF1A/4A MODY from type 2 diabetes (AUC 0.64).
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Besser and Associates(18). In contrast, UCPCR is stable at room
temperature for 3 days (21), and our re-
sults using mailed samples offer an ap-
proach that can be used in the patient’s
home or other settings away from labora-
tory equipment.
Likelihood ratios can be used to alter
the pretest probabilities, or prevalence
of a disease, to help the clinician decide
who would beneﬁt from diagnostic ge-
netic testing. Based on our results, a
UCPCR $0.2 nmol/mmol gave a likeli-
hoodratioof24,andconverselyaUCPCR
,0.2nmol/mmolwouldgivealikelihood
ratio of 0.03. This means that assuming
the prevalence of MODY is 0.7% of pa-
tientswithyoung-onsetdiabetes(24),the
posttest probability of a patient having
HNF1A/4A MODY would be 0.0002% if
UCPCR was ,0.2 nmol/mmol, allowing
genetictestingtobeexcludedonthebasis
ofasimpleurinetest.IfUCPCRispositive
($0.2 nmol/mmol) the probability of a
p a t i e n th a v i n gH N F 1 A / 4 AM O D Yi s
14%. Other nongenetic tests, such as
those for diabetes autoantibodies, and
clinical features, such as family history,
also may be useful to further modify this
probability.
UCPCR compared with other criteria
to screen for MODY versus type 1
diabetes
Littleworkhasbeendoneonbiomarkersto
discriminate MODY from type 1 diabetes.
The monosaccharide 1,5-anhydroglucitol
wasunabletodiscriminate HNF1AMODY
fromtype1diabetes(10,13).Animportant
biomarker would be pancreatic autoanti-
bodies, and this is likely to be a better test
than C-peptide close to diagnosis. Al-
though70–96%ofpatientswithtype1di-
abetes have autoantibodies, if multiple
antibodiesaretestedatdiagnosis,thispos-
itive rate falls off in the years after diagno-
sis (25). No studies have been done to
systematically determine the autoanti-
body prevalence in MODY, but it is likely
that autoantibody measurements will be
better closer to diagnosis but less sensitive
and speciﬁc 5 years after diagnosis than
UCPCR measurement.
Although parental history has rela-
tively good sensitivity (91%) in identify-
ingMODY,itfallsdownonthe speciﬁcity
(77%) (Table 1), which would increase
the number of patients who are falsely
identiﬁed as having MODY. In contrast,
t h r e eo rm o r eg e n e r a t i o n sh a v eg o o d
speciﬁcity (91%) but only modest sensi-
tivity (83%) (Table 1), which would miss
cases of MODY. Using parental history or
multigenerational family history in isola-
tionislikelytomisscasesattributedtothe
selection bias for screening patients using
traditional MODY criteria. The advantage
of using UCPCR is that it has both strong
sensitivity (97%) and speciﬁcity (96%)
for discriminating HNF1A/4A MODY
from type 1 diabetes.
UCPCR in discriminating type 2
diabetes from HNF1A/4A MODY
UCPCR was less robust at discriminating
HNF1A/4A MODY from type 2 diabetes,
comparedwith type1 diabetes. AUCPCR
value #3.1 nmol/mmol was 81% sensi-
tive and 44% speciﬁc for HNF1A/4A
MODY compared with type 2 diabetes.
This will reﬂect that in MODY the pre-
dominant defect is insulin secretion
rather than the combined defect seen in
type 2 diabetes of insulin secretion and
insulin resistance, resulting in higher C-
peptide whether measured in serum or
urine. This level of discrimination, al-
though signiﬁcant (P =0 . 0 7 ) ,i sh a r dt o
use in clinical practice in contrast to the
discrimination against type 1 diabetes.
UCPCR compared with other
biomarkers to screen for MODY
versus type 2 diabetes
1.5-AG and the proteins apolipoprotein
M, C5, C8, and TTR all have been iden-
tiﬁed as potential biomarkers for discrim-
inating HNF1A/4A MODY from type 2
diabetes (9–12), but the utility of these in
clinical practice is unclear. Although they
could discriminate between HNF1A
MODYandtype2diabetes,thesensitivity
and speciﬁcity were not sufﬁciently pow-
ered to be clinically useful (sensitivity/
speciﬁcity [%]: TTR 80/2, C5 90/11, and
C8 60/5). The sensitivity (81%) and spec-
iﬁcity (44%) of UCPCR to identify
HNF1A/4A MODY from type 2 diabetes
is higher than seen for these other bio-
markers but probably not useful as a di-
agnostic tool. UCPCR may, however,
have a role in identifying type 2 diabetes
in patients with high UCPCR levels, and
in those who are insulin treated, but fur-
ther investigation will be required to as-
sess this in a clinical setting.
Limitations
This study includes patients with long-
duration diabetes $5 years to ensure pa-
tients are outside the honeymoon period
of type 1 diabetes. Additional studies are
needed with a shorter duration to assess
the role of UCPCR in patients closer to
diagnosis. However,thevalue ofanegative
test within 5 years of diagnosis may be of
useandislikelytobeasstrongifnotstron-
ger than outside the honeymoon period.
Our study is cross-sectional, and a
prospective study with serial measurement
would let the evolution of changes in
UCPCR be assessed in all of the different
subtypes of diabetes.
Our patients only were included if
they had normal renal function because
C-peptide metabolism largely occurs in
the kidney (20). The utility of UCPCR in
renal impairment remains to be estab-
lished. These caveats prove that our re-
sults should not be extrapolated to
patients within 5 years of diagnosis or
with renal impairment until other studies
are performed.
Persistent C-peptide in type 1
patients
Itisimportanttoappreciate that C-peptide
may persist in type 1 diabetes. In our
cohort, 3 of 69 (4%) type 1 diabetic
patients had detectable C-peptide $5
years after diagnosis. They probably rep-
resent unusual type 1 diabetes or an
unidentiﬁed subtype, because autoanti-
bodies were detected in two of three pa-
tients. The DCCT found that in 5 years
after diagnosis, 3–7% type 1 diabetic pa-
tients had stimulated C-peptide .200
pmol/L (14).
In conclusion, UCPCR is a useful,
simple, noninvasive biomarker for dis-
criminating HNF1A and HNF4A MODY
from long-duration type 1 diabetes.
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